Vascular News and Research

RSS

PLC Systems second-quarter total revenues decrease to $1,019,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and six month periods ended June 30, 2010.

16 Aug 2010

UT System Board of Regents approve plans for new University Hospital at UT Southwestern Medical Center

The UT System Board of Regents today gave its approval to plans for a new state-of-the-art University Hospital at UT Southwestern Medical Center in Dallas. The project now will go to the Texas Higher Education Coordinating Board for its review and final approval.

13 Aug 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

A significant milestone has been reached in the development of a new therapy for patients suffering from coronary artery disease. On July 27, 2010 the BIOTRONIK DREAMS (Drug Eluting Absorbable Metal Scaffold) was successfully implanted in the first patient by Prof. Dr. Michael Haude at the Lukaskrankenhaus in Neuss, Germany as part of the first-in-man clinical study BIOSOLVE-I.

13 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

CPF urges people to consider clinical trials for pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is urging the more than 128,000 people known to suffer from the deadly lung disease, pulmonary fibrosis (PF), to consider clinical trials, including two new ones funded by the National Institutes of Health (NIH). Clinical trials of potential drug therapies are critical to the discovery of treatments for any disease and for a disease like PF that claims as many lives each year as breast cancer with virtually no survivors, they are the likely path to answers and saved lives.

13 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

Clinical cases that use IQQA-Liver for operative assessments exceed 1000: EDDA Technology

EDDA Technology announced today that the number of clinical cases evaluated for pre- and post- operative assessment using IQQA-Liver in hospitals has exceeded 1000 examinations, since the first commercial system installation in Q2 2009. EDDA's IQQA-Liver, now marketed worldwide, is a comprehensive workflow solution supporting modern multidisciplinary liver imaging evaluation and management.

12 Aug 2010

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

BioGenerator, a non-profit, seed-stage economic development funding group, today announced that it has led a round of early-stage financing for Pulse Therapeutics, Inc., a St. Louis company headquartered at the Center for Emerging Technologies. Pulse Therapeutics develops innovative magnetism-based technology to safely destroy blood clots related to ischemic stroke and deep vein thrombosis (DVT). Other investors who participated in the round were Missouri Technology Corporation (MTC), Washington University's Olin School of Business Skandalaris Student Venture Fund, and Integrated Magnetics, of Culver City, California. The funds will be used for further pre-clinical development.

12 Aug 2010

Endologix responds to Bard Peripheral Vascular's patent infringement lawsuit

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink® System, infringes on Bard Peripheral's "Prosthetic Vascular Graft" patent (U.S. Patent No. 6,436,135).

12 Aug 2010

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Sinobiopharma, Inc., an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases.

11 Aug 2010

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal fourth quarter and year ended June 30, 2010.

11 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.

10 Aug 2010

Hemodialysis with AVF depends on patient’s health insurance: Study

Kidney disease patients insured by some federally sponsored national health care organizations are more likely to undergo an important predialysis procedure than patients with other types of insurance, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results may provide insights into ways to improve kidney-related care for patients before they go on dialysis.

10 Aug 2010

Aptus reports successful treatment with EndoStapling System in Europe

Aptus Endosystems Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced that several patients with aortic aneurysm disease have been successfully treated with the Aptus EndoStapling System in Europe. The innovative helical staple technology enables independent endograft fixation, and is designed to approximate suturing in an open surgical anastomosis. The company continues to build on its U.S. clinical experience which includes 176 patients and deployment of more than 900 EndoStaples.

9 Aug 2010

Vanguard to acquire assets of Arizona Heart Hospital

MedCath Corporation, and its physician partners jointly announced today they have entered into a definitive agreement for Vanguard Health Systems to acquire substantially all the assets of Arizona Heart Hospital. The transaction is expected to close during MedCath's first quarter of fiscal 2011, which ends on December 31, 2010, subject to certain closing conditions.

9 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

Vascular News and Research

PLC Systems second-quarter total revenues decrease to $1,019,000

UT System Board of Regents approve plans for new University Hospital at UT Southwestern Medical Center

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

CPF urges people to consider clinical trials for pulmonary fibrosis

Study examines impact of microvascular decompression surgery for type 2 diabetes

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Clinical cases that use IQQA-Liver for operative assessments exceed 1000: EDDA Technology

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

Endologix responds to Bard Peripheral Vascular's patent infringement lawsuit

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

China Pharma second-quarter revenue increases 22% to $16.6 million

Older Americans suffer from full-blown depression: Report

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

Hemodialysis with AVF depends on patient’s health insurance: Study

Aptus reports successful treatment with EndoStapling System in Europe

Vanguard to acquire assets of Arizona Heart Hospital

EpiCept second-quarter net loss decreases to $4.9 million

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News